Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance

被引：59

作者：

Pieren, Michel ^{[1
]}

Tigges, Marcel ^{[1
]}

机构：

[1] BioVersys AG, Technologyctr, CH-4057 Basel, Switzerland

来源：

CURRENT OPINION IN PHARMACOLOGY | 2012年 / 12卷 / 05期

关键词：

SMALL-MOLECULE INHIBITORS; MULTIDRUG-RESISTANCE; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; EFFLUX PUMPS; MECHANISMS; ETHR; SYSTEM; AGENTS;

D O I：

10.1016/j.coph.2012.07.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Alarming facts about the occurrence and spreading of multiple antibiotic resistant bacteria have caught the attention of global surveillance authorities and public media. The demand for novel effective antimicrobial drugs is high and on the rise while, at the same time, the supply of fresh 'magic bullets' is drying up. This review summarizes examples of recent strategies for development of adjunctive antibiotic therapies that overcome microbial resistance and thus rejuvenate the existing arsenal of drugs. Recent studies have demonstrated the potential of compounds that inhibit the action of the repressor protein implicated in ethionamide resistance, thus stimulating activation of the drug and thereby restoring the activity of the antibiotic for treatment of Mycobacterium tuberculosis. Such specific interference with regulators or signal transduction mechanisms involved in antibiotic resistance or virulence provides a new toolbox for novel combinations of antimicrobial drugs with adjuvant molecules lacking intrinsic antibiotic activity. In addition to the development of new antibiotics and vaccination initiatives this strategy of restoring or potentiating the activity of existing antibiotics may help to postpone the day when antibiotics are no longer generally efficacious.

引用

页码：551 / 555

页数：5

共 52 条

[1] Phage Therapy Pharmacology [J].

Abedon, Stephen T. ;

Thomas-Abedon, Cameron .

CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2010, 11 (01) :28-47

[2] Molecular mechanisms of antibacterial multidrug resistance [J].

Alekshun, Michael N. ;

Levy, Stuart B. .

CELL, 2007, 128 (06) :1037-1050

[3] Heterogeneous bacterial persisters and engineering approaches to eliminate them [J].

Allison, Kyle R. ;

Brynildsen, Mark P. ;

Collins, James J. .

CURRENT OPINION IN MICROBIOLOGY, 2011, 14 (05) :593-598

[4] Antibiotic resistance and its cost: is it possible to reverse resistance? [J].

Andersson, Dan I. ;

Hughes, Diarmaid .

NATURE REVIEWS MICROBIOLOGY, 2010, 8 (04) :260-271

[5] Novel anti-infection agents: Small-molecule inhibitors of bacterial transcription factors [J].

Bowser, Todd E. ;

Bartlett, Victoria J. ;

Grier, Mark C. ;

Verma, Atul K. ;

Warchol, Taduesz ;

Levy, Stuart B. ;

Alekshun, Michael N. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (20) :5652-5655

[6] Th GacS/GacA signal transduction system of Pseudomonas aeruginosa acts exclusively through its control over the transcription of the RsmY and RsmZ regulatory small RNAs [J].

Brencic, Anja ;

McFarland, Kirsty A. ;

McManus, Heather R. ;

Castang, Sandra ;

Mogno, Ilaria ;

Dove, Simon L. ;

Lory, Stephen .

MOLECULAR MICROBIOLOGY, 2009, 73 (03) :434-445

[7] The global need for effective antibiotics-Moving towards concerted action [J].

Cars, Otto ;

Hedin, Anna ;

Heddini, Andreas .

DRUG RESISTANCE UPDATES, 2011, 14 (02) :68-+

[8] Antibiotic interactions that select against resistance [J].

Chait, Remy ;

Craney, Allison ;

Kishony, Roy .

NATURE, 2007, 446 (7136) :668-671

[9]

Chevalier J, 2004, ANTIMICROB AGENTS CH, V48, P1335

[10] A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates [J].

Coban, AY ;

Ekinci, B ;

Durupinar, B .

CHEMOTHERAPY, 2004, 50 (01) :22-26

← 1 2 3 4 5 6 →